Efzofitimod Phase 2 study for SSc-ILD planned to launch in 2023
aTyr Pharma plans to test efzofitimod, its lead candidate for treating interstitial lung disease (ILD) associated with systemic sclerosis (SSc), in a Phase 2 clinical study this year in the U.S. The plans come after the U.S. Food and Drug Administration (FDA) cleared an investigational new drug…